Customer concentration
A small number of distributors, HME providers, and partners generate a large share of revenue, so lost volume can materially reduce sales.
- Scope
- Top 10 customers were 38.9% of 2025 revenue
- Materiality
- high
Inogen Inc
Inogen Inc designs, markets, and sells portable and stationary oxygen concentrators and related respiratory products for people needing long-term oxygen therapy. The company sells through a mix of U.S. business-to-business channels, direct-to-consumer channels, and international distributors, with a growing emphasis on expanding its respiratory product portfolio and overseas reach.
−2,7 %
44,2 %
−6,5 %
+3,9 %
3.12
2.71
| % | |
|---|---|
| Portable oxygen concentrators | 55% Battery-powered and portable oxygen therapy devices sold to patients and channel partners. |
| Stationary oxygen concentrators | 10% Home-use oxygen concentrators, including the Voxi 5 introduced through the Yuwell collaboration. |
| Oxygen rentals | 15% U.S. rental revenue from concentrator deployments to patients on service. |
| Accessories and replacement parts | 10% Consumables, replacement components, and related support items for installed devices. |
| Partner-distributed respiratory products | 10% Third-party respiratory products distributed in the U.S. and selected international markets. |
Inogen sells primarily to home medical equipment providers, distributors, resellers, and other business partners that...
- U.S. business-to-business partnersprimary
HME providers, distributors, and resellers that buy concentrators to serve oxygen therapy patients and shift away from tank delivery models.
- Direct-to-consumer patientsprimary
Patients purchasing directly in the U.S. through cash or insurance-related channels, often influenced by consumer advertising and prescriber outreach.
- International distributors and house accountsprimary
Distributors, resellers, gas companies, and home oxygen providers that buy for resale or local patient support across Europe and other markets.
- Private label and strategic collaboratorssecondary
Channel partners and collaborators that broaden product access and help scale distribution into new markets and product lines.
- Charitable and institutional buyerssecondary
Smaller but relevant buyers that contribute to channel diversity and can support patient access programs.
The U.S. remains the largest market, but international sales are a major part of the business and represented 39...
- •U.S. sales were 44.9% of 2025 revenue
- •International sales were 39.8% of 2025 revenue
- •Europe accounted for 85.0% of international sales in 2025
- •Netherlands site supports European sales and customer service
- •Czech Republic contract manufacturing supports European supply
Inogen is focused on expanding its U.S. B2B channel, improving direct-to-consumer productivity, and increasing...
01
Expand domestic B2B channel penetrationshort-term
The U.S. market still has low POC penetration, so more HME and reseller adoption can drive volume growth.
02
Increase international adoptionmedium-term
Europe offers reimbursement-supported demand and the company already has a meaningful overseas base.
03
Improve direct-to-consumer executionshort-term
Better lead generation and sales productivity can offset pressure in the consumer channel.
04
Broaden the respiratory product portfoliomedium-term
New products can deepen channel relationships and reduce dependence on a narrow oxygen concentrator mix.
The business is exposed to customer concentration, reimbursement complexity, and intense competition in respiratory...
Reimbursement and payer dependence
A meaningful portion of demand depends on insurance and Medicare-related reimbursement, which can change utilization and economics.
- Scope
- U.S. rentals and insurance-supported patient channels
- Materiality
- high
Competitive pressure
The company operates in a crowded respiratory device market where rivals can win share through price, features, or channel relationships.
- Scope
- Portable oxygen concentrators and related respiratory products
- Materiality
- high
Supplier and manufacturing dependence
Reliance on contract manufacturers and limited suppliers can create quality, timing, and cost risks.
- Scope
- Foxconn in the Czech Republic and other third-party providers
- Materiality
- medium
Regulatory and compliance risk
Medical devices are subject to FDA and international regulatory oversight, and additional clearances or enforcement actions could slow launches or sales.
- Scope
- U.S., EU, and other international markets
- Materiality
- medium
Cybersecurity and IT disruption
Customer support, sales operations, and internal systems depend on networked IT infrastructure that can be attacked or fail.
- Scope
- Order processing, customer data, and support operations
- Materiality
- medium
Revenue recognition
Point-in-time product sales versus rental/service recognition
Goodwill and acquired intangible assets
Potential non-cash impairment charges
Rental asset accounting
Affects operating expenses, assets, and cash flow presentation
Allowance and credit risk
Accounts receivable valuation and bad debt expense
NEOGEN CORP
NEOG · In Vitro & In Vivo Diagnostic Substances
Neogen Corp develops and sells products and services used to test food, feed, and agricultural inputs for safety and quality, while also providing genomics and animal safety solutions.
INSULET CORP
PODD · Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes.
AIM ImmunoTech Inc.
AIM · Biological Products, (No Diagnostic Substances)
NEUROCRINE BIOSCIENCES INC
NBIX · Biological Products, (No Diagnostic Substances)
Neurocrine Biosciences is a U.S.-based biopharmaceutical company focused on neuroscience and related endocrine disorders.
UroGen Pharma Ltd.
URGN · Pharmaceutical Preparations
IN8BIO, INC.
INAB · Biological Products, (No Diagnostic Substances)
: 28.4.2026